Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis
Journal: Journal of Neurology, Neurosurgery, and Psychiatry; January 1, 2023
Author(s): Gregorio Spagni, Bo Sun, Gabriele Monte, Elia Sechi, Raffaele Iorio, Amelia Evoli, Valentina Damato
How effective is rituximab in MOGAD compared to NMOSD?
This study is a systematic review and meta-analysis, that is, it reviews all previously published papers on a topic to arrive at some conclusions. This study included 315 patients and aimed to compare the efficacy and safety of rituximab in patients with MOGAD versus NMOSD. The results showed that rituximab was effective in MOGAD patients but less so than in NMOSD patients, and it caused some side effects in MOGAD patients because of which caution should be exercised in its prescription.
Related article: Long-term effectiveness and safety of Rituximab in NMOSD and MOGAD
Free Access: Abstract only
